In many RCTs which used Sorafenib as the control group, PD-1/PD-L1 inhibitors showed superior treatment outcomes than Sorafenib, with improved therapeutic efficacy in HCC patients with EHS/MVI. The gene discussed is CD274; the disease is hepatocellular carcinoma.